Is neoadjuvant chemotherapy necessary for T2N0-1M0 hormone receptor-positive/HER2-negative breast cancer patients undergoing breast-conserving surgery?

J Cancer Res Clin Oncol · 2024 · PMC11139699 · PMID 38814494

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Thus, the use of NAC in the HR-positive/HER2-negative population showed an increasing trend (Murphy et al. 2018 ), even if the pCR rates were not comparable to those in the other two subtypes of breast cancer.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.